A phase III randomized trial found that topical 0.25% finasteride spray and oral 1 mg finasteride produced similar hair-count gains at 24 weeks, but topical use cuts systemic drug exposure dramatically. Oral finasteride carries full FDA approval for male pattern hair loss, while topical versions remain unapproved and have drawn an FDA safety alert regarding compounded formulations.
Finasteride is FDA-indicated for men only. Women who are or may become pregnant must not handle crushed or broken finasteride tablets, due to the risk of harm to a male fetus. It can also cause sexual side effects (reduced libido, erectile dysfunction) in a minority of men, which usually resolve after stopping treatment. Discuss these risks with a physician before starting.
TL;DR:
- Most head to head comparisons last only 24 weeks and involve younger men with moderate hair loss, so longer term results may differ.
- Early oral trials reported sexual side effects in 3.8% of participants, and 1.4% stopped treatment because of them; topical reports may undercount symptoms.
- Clinicians usually assess response at six months and review it fully at twelve; if improvement remains limited, they may add minoxidil rather than stop finasteride.
- Topical solution can transfer before drying; anyone applying it should wash hands, while pregnant women and those who may become pregnant should avoid contact.
- Because hair gains fade after stopping either formulation, finasteride must be continued to maintain results rather than used as a temporary course.
The clearest comparison comes from a phase III randomized trial that measured target-area hair count at 24 weeks. Topical 0.25% finasteride spray produced an adjusted mean increase of 20.2 hairs, while oral 1 mg finasteride produced 21.1 hairs, a difference small enough that the two routes performed in the same range.
Other trials and reviews reinforce this pattern: topical finasteride consistently beats placebo on hair count and investigator assessments, and in short-term studies it approximates what oral therapy delivers. A review summary of pooled trial data found no strong signal for increased sexual side effects with topical use, though the authors called for larger studies before drawing firm conclusions.
A few caveats matter when weighing this evidence:
The reason topical and oral finasteride can produce similar hair counts while carrying different risk profiles comes down to how much drug reaches the bloodstream. In the same phase III trial, plasma finasteride concentrations were more than 100 times lower with the topical spray than with the oral tablet.
Serum DHT dropped less with topical finasteride than with oral finasteride at 24 weeks, reflecting a reduced systemic impact from topical use, according to the trial’s pharmacokinetic data. That gap suggests topical application still delivers enough drug locally to shrink hair follicle miniaturization, without pushing nearly as much finasteride into general circulation.
Lower systemic exposure plausibly lowers the odds of systemic side effects, though it does not eliminate them, since topical products still produce measurable plasma levels. A few practical points follow from this:
Classic oral finasteride trials, reflected in the drug’s prescribing information, reported sexual adverse events in about 3.8% of participants, with roughly 1.4% discontinuing treatment because of them. These figures come from early registration trials and remain the reference point most clinicians cite.
Real-world data on topical finasteride tells a different story. A large retrospective telehealth study of men prescribed compounded topical finasteride found roughly 80% reported satisfaction, fewer than 3% reported any side effects, and sexual or neuropsychiatric events appeared in about 0.002% of patients, with no reports of post-finasteride syndrome in that cohort. These numbers likely understate true incidence somewhat, since retrospective reporting depends on patients volunteering symptoms, and the studies are not powered to catch very rare events.
Regulators have also flagged a separate concern. The FDA’s compounding alert cites 32 adverse event reports submitted to FAERS between 2019 and 2024 tied to compounded topical finasteride, and notes that compounded products never go through FDA review for safety, quality, or labeling consistency.
Pro Tip: Track mood changes, libido, and scalp irritation in the weeks after starting either formulation, and report any new or worsening symptoms to your prescriber at your next check-in rather than waiting for a scheduled follow-up.
Getting a fair read on either formulation takes patience. Here’s how clinicians typically structure the process:
Handling topical products safely means letting the solution dry fully before contact with pillows or a partner’s skin, and washing hands immediately after each application.
We built our hair loss program around the same principle this research points to: matching the treatment route to the patient, not defaulting to one option for everyone. Our platform connects you with licensed providers who review your history and decide whether oral finasteride, topical formulations, or minoxidil combinations fit your situation best.
The pathway is straightforward. You complete an intake covering your medical history and goals, a licensed clinician reviews it and determines whether finasteride, minoxidil, or a combination makes sense, and if prescribed, medication is shipped to your door with ongoing support through an app for questions or dose adjustments.
For men comfortable relying on decades of established data, oral finasteride remains the default choice, and it still has the deepest evidence base. For men who want to limit systemic exposure or who’ve had side effects on oral therapy, topical finasteride offers a reasonable alternative supported by short-term trials and encouraging real-world tolerability data.
Either path works best with periodic monitoring and a willingness to combine or switch if results stall.
— Bryan
Deciding between oral and topical finasteride doesn’t have to happen alone. We match you with a licensed provider who reviews your history and recommends a plan built around your actual risk tolerance and goals, whether that’s oral finasteride, a topical option, or a combination approach.
Our hair loss program includes a clinician consultation, a prescription when appropriate, medication delivered to your home, and app-based follow-up so you’re not guessing whether treatment is working. If combination therapy with minoxidil makes sense for your situation, your provider can walk you through how topical minoxidil timelines typically unfold alongside finasteride. Book a consultation through our hair loss page to get a personalized plan started.
This article is general information, not a substitute for advice from a qualified doctor. Consult a qualified healthcare professional about your own circumstances before acting on anything here.
Trial data show topical 0.25% spray produced hair-count gains close to oral finasteride at 24 weeks, with 20.2 versus 21.1 hairs in target-area counts. Long-term comparative data is more limited than for oral therapy, which has decades of follow-up.
Early trials of oral finasteride reported sexual side effects in about 3.8% of participants, with about 1.4% discontinuing treatment because of them. Mood changes and scalp irritation are also reported, though less frequently than sexual side effects.
Finasteride and minoxidil work through different mechanisms, finasteride reduces DHT production while minoxidil improves blood flow to follicles, so they’re often used together rather than compared head-to-head. Clinicians frequently add minoxidil when finasteride alone doesn’t produce enough improvement by six to twelve months.
No, compounded topical finasteride is not FDA-approved, and the FDA issued an alert after receiving 32 adverse event reports between 2019 and 2024. Compounded products also lack the standardized quality and labeling review that approved medications undergo.
Most clinicians recommend assessing results around six months, with a fuller evaluation at twelve months of consistent use. Results typically reverse within a year of stopping treatment, so maintaining the regimen is necessary to keep any gains.
.svg)
